BASIC STUDY AND PHASE I CLINIC TRIAL OF ANTI-IDIOTYPIC ANTIBODY MIMICKING NASOPHARYNGEAL CARCINOMA CELL ANTIGEN

Becauseofthespecialroleofanti-idiotypic(anti-id)antibodies(Abs)inimmunenetwork,itspotentialroleintumorimmunotherapyandimmunopreventionhasdrawnwideinterest.Anti-idAbsmimickingcoIorectalcarcinoma-associatedantigenandhumanhighmolecularweightmelanoma-associatedantigen(HMW-MAA)havebeenpreparedandtriedforactiveimmunotherapyontumorpatients.l-6Buttherehasn'tbeenanyrepoftaboutanti-idAbofnasopharyngealcarcinoma(NPC).NPCisatumorwithhighepidemicincidenceinChinaandSoutheastAsia,therehasn'tbeenmuchst…

Basic study and phase I clinic trial of anti-idiotypic antibody mimicking nasopharyngeal carcinoma cell antigen

An anti-idiotypic monoclonal antibody 2A9 (Ab2) was prepared, which mimicked the nasopharynegeal carcinoma (NPC) cell antigen defined by anti-NPC McAb Fcl. The abilities of 2A9’s inducing humoral and cellular immunity against NPC cell antigen were studied in syngeneic mice by inducing anti-Ab2 sera (Ab3) and delayed-type hypersensitivity. Two periods of phase 1 clinical trials were carried out, stage IV NPC patients receiving radiotherapy were chosen. Human anti-mouse antibodies (HAMA), anti-anti-idiotypic antibodies (Ab3), and anti-NPC cell antibodies (Abl′) were detected by ELISA. TNF-α,IL-2, IFN-γ levels in sera were determined by ELISA Kits. IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) were shown byin situ hybridization. The results showed that 2A9 was safe in applying on NPC patients and induced some humoral and/or cellular immune responses.